company background image
CGEM

Cullinan Oncology NasdaqGS:CGEM Stock Report

Last Price

US$11.15

Market Cap

US$438.5m

7D

4.8%

1Y

-13.2%

Updated

27 Jan, 2023

Data

Company Financials +

Cullinan Oncology, Inc.

NasdaqGS:CGEM Stock Report

Mkt Cap: US$438.5m

CGEM Stock Overview

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States.

CGEM fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Cullinan Oncology, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cullinan Oncology
Historical stock prices
Current Share PriceUS$11.15
52 Week HighUS$15.89
52 Week LowUS$7.30
Beta0.0065
1 Month Change10.18%
3 Month Change-18.14%
1 Year Change-13.16%
3 Year Changen/a
5 Year Changen/a
Change since IPO-62.72%

Recent News & Updates

Recent updates

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Jun 24
Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Mar 05
Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Oct 08
Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Shareholder Returns

CGEMUS BiotechsUS Market
7D4.8%0.7%2.3%
1Y-13.2%7.1%-9.7%

Return vs Industry: CGEM underperformed the US Biotechs industry which returned 10.5% over the past year.

Return vs Market: CGEM underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is CGEM's price volatile compared to industry and market?
CGEM volatility
CGEM Average Weekly Movement6.8%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: CGEM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CGEM's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201637Nadim Ahmedhttps://www.cullinanoncology.com

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company’s lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein.

Cullinan Oncology, Inc. Fundamentals Summary

How do Cullinan Oncology's earnings and revenue compare to its market cap?
CGEM fundamental statistics
Market CapUS$438.47m
Earnings (TTM)US$105.48m
Revenue (TTM)n/a

4.2x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CGEM income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other Expenses-US$105.48m
EarningsUS$105.48m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.68
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CGEM perform over the long term?

See historical performance and comparison